Voliotis Dimitris 4
4 · Zentalis Pharmaceuticals, Inc. · Filed Feb 16, 2021
Insider Transaction Report
Form 4
Voliotis Dimitris
SVP, Clinical Development
Transactions
- Award
Common Stock
2021-02-11+6,250→ 6,250 total - Award
Stock Option (Right to Buy)
2021-02-11+18,750→ 18,750 totalExercise: $38.76Exp: 2031-02-10→ Common Stock (18,750 underlying)
Footnotes (2)
- [F1]Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date.
- [F2]The option vests and becomes exercisable in 48 substantially equal monthly installments following the grant date.